Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 187 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: RIF Clear all
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

NCT00864487
View directory record Official record
Conditions
Healthy Subjects
Interventions
Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Not applicable Interventional

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000636
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
25
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions

NCT00621309
View directory record Official record
Conditions
Adverse Drug Interactions
Interventions
Rifampicin, sulforaphane plus rifampicin, sulforaphane alone
Drug · Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 40 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 2Phase 3 Interventional

Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease

NCT03672630
View directory record Official record
Conditions
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
Interventions
Azithromycin, Ethambutol, Rifampin
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
25
States / cities
Loma Linda, California • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort

NCT02286635
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Deflazacort and rifampin, Deflazacort and Clarithromycin
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

NCT06004947
View directory record Official record
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Warfarin Induction and Inhibition

NCT01447511
View directory record Official record
Conditions
Healthy
Interventions
Control - Warfarin only, Fluconazole - Warfarin, Rifampin - Warfarin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 26, 2026, 9:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants

NCT04558216
View directory record Official record
Conditions
Healthy Participants
Interventions
Vonoprazan, Rifampin
Drug
Lead sponsor
Phathom Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Results available

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

NCT00925756
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

NCT00585195
View directory record Official record
Conditions
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions
PF-02341066, Rifampin, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
24
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

NCT01765543
View directory record Official record
Conditions
Malignant Melanoma, Neoplasms
Interventions
Rifampin, Vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Rogers, Arkansas • Pleasant Hill, California • Middletown, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

NCT02411435
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
CAB, RIF
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rifampin and the Contraceptive Implant

NCT04463680
View directory record Official record
Conditions
Contraception, Tuberculosis
Interventions
Rifampin 600 MG
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Evacetrapib and Rifampin in Healthy Participants

NCT01908582
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evacetrapib, Rifampin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

NCT03311841
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 78 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

NCT03563950
View directory record Official record
Conditions
Healthy Participants
Interventions
Rifampin, BMS-986224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers

NCT02545439
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional

Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

NCT01401933
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Linifanib, Rifampin
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Tucson, Arizona • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Oct 26, 2026, 9:09 PM EDT
Completed No phase listed Observational

Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

NCT00720980
View directory record Official record
Conditions
Granuloma Annulare
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 26, 2026, 9:09 PM EDT
Withdrawn Phase 1 Interventional

A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer

NCT00534807
View directory record Official record
Conditions
Cancer
Interventions
Vinflunine, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 26, 2026, 9:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Rifampin on Single-Dose Pharmacokinetics of Canagliflozin in Healthy Volunteers

NCT01395927
View directory record Official record
Conditions
Healthy
Interventions
Rifampin, Canagliflozin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Oct 26, 2026, 9:09 PM EDT